Quince Therapeutics has filed a patent for compounds that can inhibit the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. The patent also includes methods for assaying gingipain activity and treating disorders associated with P. gingivalis infection, including Alzheimer’s disease. GlobalData’s report on Quince Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Quince Therapeutics, human telomerase RT biomarker was a key innovation area identified from patents. Quince Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibiting the lysine gingipain protease from porphyromonas gingivalis
A recently filed patent (Publication Number: US20230142714A1) describes a compound and its pharmaceutical applications. The compound, referred to as Formula I, is the subject of the patent claims. The compound can exist in various forms, including pharmaceutically acceptable salts.
The patent claims specify different variations of the compound, including the possible substitutions and configurations of its components. For example, R3, one of the components of the compound, can be selected from a group of options such as cycloalkyl, alkyl, aryl, heteroaryl, and heterocyclyl, each of which can be optionally substituted with one or more R3a substituents. R3a can be independently selected from options like halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, and various other groups.
The claims also describe specific structures and configurations of the compound, such as Formula Ia. Additionally, the claims mention the possibility of R4 being hydrogen and R5a being substituted phenyl with halogens.
The patent claims further discuss the compound's applications in pharmaceutical compositions and methods of treating diseases or conditions associated with P. gingivalis infection. The diseases or conditions can include brain disorders, periodontal disease, diabetes, cardiovascular disease, arthritis, preterm birth risk, pneumonia, cancer, kidney disease, liver disease, retinal disorders, and glaucoma.
Specifically, the patent claims highlight the potential use of the compound in treating brain disorders, including Alzheimer's disease, Down's syndrome, epilepsy, autism, Parkinson's disease, and various other conditions. The claims also mention the possibility of administering additional active agents alongside the compound for enhanced therapeutic effects. These agents can include cholinesterase inhibitors, serotonin modulators, NMDA modulators, Aß targeted therapies, ApoE targeted therapies, microglia targeted therapies, blood-brain barrier targeted therapies, tau targeted therapies, complement targeted therapies, and anti-inflammatory agents.
In summary, the patent claims describe a compound and its various configurations, as well as its potential applications in pharmaceutical compositions and the treatment of diseases or conditions associated with P. gingivalis infection, particularly brain disorders like Alzheimer's disease. The claims also suggest the possibility of combining the compound with other active agents for improved therapeutic outcomes.
To know more about GlobalData’s detailed insights on Quince Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
